Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
First all-oral XDR-TB drug regimen trial launches in South Africa

The regimen is comprised of bedaquiline, which received provisional approval from the U.S. Food and Drug Administration in 2013 to treat drug-resistant tuberculosis, pretomanid a new type of antibacterial drug, and linezolid which is used off-label to treat TB.

Published
15 May 2015
From
Science Speaks
WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others.

Published
11 May 2015
From
World Health Organization
Final fight pays off, XXDR-TB & HIV patient cured

Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

Published
24 March 2015
From
DNAIndia
MSF: More than a quarter of MDR-TB cases in Swaziland not caught by “front line of defense” in fighting the disease

The nonprofit medical humanitarian organization Médecins Sans Frontières is recommending that all patients in Swaziland who have tested positive for TB, but rapid molecular testing has found negative for drug-resistance undergo further testing, following findings that a mutation has made more than a quarter of multidrug-resistant strains undetectable by the widely used test.

Published
20 March 2015
From
Science Speaks
Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

Published
18 March 2015
From
Lancet (free registration required)
Tuberculosis and superbug strains 'ravaging' Europe, WHO warns

As many as 1,000 people a day in Europe contract tuberculosis, and slow progress against the disease coupled with rising drug resistance mean the region is unlikely to defeat it until next century, health officials said on Tuesday.

Published
17 March 2015
From
Reuters
XDR-TB in South Africa is largely spread person-to-person, not by failure of drug treatment

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the

Published
26 February 2015
By
Keith Alcorn
UGA researchers discover potential treatment for drug-resistant tuberculosis

The compound Nair and his colleagues developed works by binding to magnesium and specific amino acids found within the bacterium, interrupting the production of RNA. They were surprised to discover through preliminary experiments that it also exhibited strong anti-HIV properties, opening the door for dual therapeutic applications.

Published
20 February 2015
From
University of Georgia press release
Addressing TB and drug-resistant TB in the Eastern Ukrainian region

The challenges in addressing the implementation of comprehensive HIV, TB and viral hepatitis prevention and treatment activities in the Eastern Ukraine affected by the warfare is complicated and escalating every week.

Published
11 February 2015
From
Stop TB Partnership
Access sought to tuberculosis drug from nutraceutical company

Delamanid, only the second tuberculosis drug approved in 40 years by European regulators, uses a new mechanism of action to treat the disease by inhibiting the synthesis of a cell-wall component of Mycobacterium tuberculosis, the bacterium that causes tuberculosis. But patient advocates worry that the new drug may not reach the patients who need it because, according to these advocates, the developer of the drug has failed to aggressively study and market the medication in regions that need it most.

Published
05 February 2015
From
Nature Medicine
← First12345...19Next →

Filter by country